Analyst Price Targets — ABBV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 4:29 pm | — | UBS | $260.00 | $247.05 | TheFly | AbbVie price target raised to $260 from $230 at UBS |
| July 13, 2026 12:20 pm | — | BMO Capital | $300.00 | $246.69 | TheFly | AbbVie price target raised to $300 from $258 at BMO Capital |
| July 10, 2026 11:30 am | Trung Huynh | RBC Capital | $280.00 | $246.80 | StreetInsider | Abbvie (ABBV) PT Raised to $280 at RBC Capital |
| July 10, 2026 10:18 am | — | Wells Fargo | $295.00 | $249.91 | TheFly | AbbVie price target raised to $295 from $260 at Wells Fargo |
| July 9, 2026 11:26 am | — | Guggenheim | $261.00 | $252.61 | TheFly | AbbVie price target raised to $261 from $249 at Guggenheim |
| July 6, 2026 2:19 pm | — | HSBC | $300.00 | $255.17 | TheFly | AbbVie price target raised to $300 from $275 at HSBC |
| July 6, 2026 11:04 am | — | Cantor Fitzgerald | $265.00 | $261.07 | TheFly | AbbVie price target raised to $265 from $240 at Cantor Fitzgerald |
| June 23, 2026 10:55 am | — | Canaccord Genuity | $273.00 | $230.06 | TheFly | AbbVie price target raised to $273 from $265 at Canaccord |
| June 22, 2026 10:16 am | — | Wells Fargo | $260.00 | $216.63 | TheFly | AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo |
| May 15, 2026 12:20 pm | — | Evercore ISI | $235.00 | $212.05 | TheFly | AbbVie price target lowered to $235 from $236 at Evercore ISI |
Latest News for ABBV
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹ Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks Boey® offers a differentiated treatment option for many people who are curious about facial injectables²…
ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.
AbbVie ABBV stock has risen 8.9% so far this year as investor confidence strengthened in the company's post-Humira growth strategy. Despite Humira's U.S. patent expiry in 2023, AbbVie has successfully replaced much of the blockbuster's lost revenues with strong growth from Skyrizi and Rinvoq, easing concerns over its long-term earnings outlook.
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-day.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.